CDX-110 Vaccine May Improve Survival in Brain Cancer (6/5/2008)
Researchers affiliated with the ACTIVATE and ACT II trials have reported that the investigative vaccine CDX-110 has demonstrated impressive survival results when compared with historical controls for patients with glioblastoma multiforme (GBM). These results were recently presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois.

Avastin® Improves Survival in Recurrent Brain Cancer (6/4/2008)
Researchers from the University of California at Los Angeles have reported that patients with recurrent glioblastoma who were treated with Avastin® (bevacizumab) alone experienced a slight survival advantage compared with patients treated with Avastin plus Camptosar® (irinotecan). These results were presented at the 2008 annual meeting of the American Society of Clinical Oncology.

Cediranib Prolongs Survival in Recurrent Glioblastoma (5/29/2008)
Researchers from the Massachusetts General Hospital, the National Cancer Institute, and the Dana Farber Cancer Center have reported that cediranib (AZD2171) appears to prolong survival among patients with recurrent glioblastoma multiforme (GBM). These results were at the American Association for Cancer Research (AACR) 2008 annual meeting April 12-16 in San Diego.

Clinical Course of Newly Diagnosed Glioblastoma Described (4/23/2008)
Researchers from Italy have reported the prognostic characteristics of more than 600 consecutive cases of newly diagnosed glioblastoma. The details of this study were published in the February 2008 issue of Neuro-Oncology.

Avastin® and Camptosar® Effective for Recurrent Gliomas (3/19/2008)
Researchers from Israel have reported that the combination of Avastin® (bevacizumab) and Camptosar® (irinotecan) is an effective combination for the treatment of recurrent high-grade gliomas. The details of this Phase II study were published early online on March 8, 2008 in Cancer.